MARKET

EGRX

EGRX

Eagle Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.17
+0.52
+1.09%
After Hours: 48.17 0 0.01% 16:08 07/28 EDT
OPEN
47.67
PREV CLOSE
47.65
HIGH
48.38
LOW
47.45
VOLUME
79.55K
TURNOVER
--
52 WEEK HIGH
53.43
52 WEEK LOW
36.48
MARKET CAP
631.48M
P/E (TTM)
45.21
1D
5D
1M
3M
1Y
5Y
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Eagle Pharmaceuticals' (NASDAQ:EGRX) stock increased significantly by 17% over...
Simply Wall St. · 07/14 06:28
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 07/02 19:30
BRIEF-Eagle Pharmaceuticals Announces FDA Maintains Prioritization Of ANDA For Vasopressin
reuters.com · 06/24 10:56
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug and Administration ("FDA") has maintained Priority Review for the Company's Abbreviated New Drug Application ("ANDA") for vasopressin. The Com...
Business Wire · 06/24 10:50
Eagle Pharmaceuticals Says FDA Maintains Priority Review of Abbreviated New-Drug Application for Vasopressin
MT Newswires · 06/24 07:27
BRIEF-Eagle Pharmaceuticals Submits Response To Complete Response Letter From FDA For Vasopressin
reuters.com · 06/17 11:03
Eagle Pharmaceuticals Submits Response to FDA's Complete Response Letter for Vasopressin
MT Newswires · 06/17 09:35
Return On Capital Employed Overview: Eagle Pharmaceuticals
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. Eagle Pharmaceuticals earned $9.79 million, and sales totaled $49.92 million in Q4.
Benzinga · 06/04 14:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EGRX. Analyze the recent business situations of Eagle Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EGRX stock price target is 47.33 with a high estimate of 50.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 250
Institutional Holdings: 15.72M
% Owned: 119.88%
Shares Outstanding: 13.11M
TypeInstitutionsShares
Increased
62
944.37K
New
14
202.92K
Decreased
55
1.01M
Sold Out
19
98.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.13%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Non-Executive Chairman/Independent Director
Michael Graves
President/Chief Operating Officer
David Pernock
Chief Executive Officer/Director
Scott Tarriff
Chief Financial Officer
Brian Cahill
Executive Vice President
Judith Ng-Cashin
Independent Director
Luciana Borio
Independent Director
Richard Edlin
Independent Director
Robert Glenning
Independent Director
Steven Ratoff
Independent Director
Jennifer Simpson
No Data
About EGRX
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.